High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation

Biochemical and Biophysical Research Communications

Volumn 358, Issue 1, 2007, Pages 1-6

  Crowe, Alex ^a   Ballatore, Carlo ^b   Hyde, Edward ^a   Trojanowski, John Q ^a   Lee, Virginia M Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer's disease; Fibrillization; FTDP 17; High throughput screening; Inhibitor; Microtubule associated protein tau

Indexed keywords

2,3 DI(FURAN 2 YL)QUINOXALINE DERIVATIVE; ANTHRAQUINONE; BENZOFURAN DERIVATIVE; DEPSIDONE DERIVATIVE; DITHIOTHREITOL; HEPARIN; PHENOTHIAZINE DERIVATIVE; PORPHYRIN DERIVATIVE; PYRIMIDOTRIAZINE DERIVATIVE; QUINOXALINE DERIVATIVE; TAU PROTEIN; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; DRUG INHIBITION; DRUG SCREENING; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; IC 50; LABORATORY DIAGNOSIS; MOLECULE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL;

DRUG EVALUATION, PRECLINICAL; FLUORESCENCE; FLUORESCENT DYES; FURANS; HEPARIN; NEUROFIBRILLARY TANGLES; QUINOXALINES; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TAU PROTEINS; THIAZOLES;

EID: 34248142548     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.03.056     Document Type: Article

References (10)

1. Ross C.A., and Poirier M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 10 Supp. l (2004) S10-S17
2. Skovronsky D.M., Lee V.M.Y., and Trojanowski J.Q. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu. Rev. Pathol.: Mech. Disease 1 1 (2006) 151-170
3. Trojanowski J.Q., Smith A.B., Huryn D., and Lee V.M.-Y. Microtubule-stabilizing drugs for therapy of Alzheimer's disease and other neurodegenerative disorders with axonal transport impairments. Exp. Opin. Pharmacother. 6 5 (2005) 683-686
4. Wischik C.M., Edwards P.C., Lai R.Y.K., Roth M., and Harrington C.R. Selective inhibition of Alzheimer disease-like tau aggregation by†phenothiazines. PNAS 93 20 (1996) 11213-11218
5. Chirita C., Necula M., and Kuret J. Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 43 10 (2004) 2879-2887
6. Pickhardt M., Gazova Z., von Bergen M., Khlistunova I., Wang Y., Hascher A., Mandelkow E.M., Biernat J., and Mandelkow E. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J. Biol. Chem. 280 5 (2005) 3628-3635
7. Taniguchi S., Suzuki N., Masuda M., Hisanaga S., Iwatsubo T., Goedert M., and Hasegawa M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280 9 (2005) 7614-7623
8. McGovern S.L., Caselli E., Grigorieff N., and Shoichet B.K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45 8 (2002) 1712-1722
9. McGovern S.L., Helfand B.T., Feng B., and Shoichet B.K. A specific mechanism of nonspecific inhibition. J. Med. Chem. 46 20 (2003) 4265-4272
10. Guertin K.R., Setti L., Qi L., Dunsdon R.M., Dymock B.W., Jones P.S., Overton H., Taylor M., Williams G., Sergi J.A., Wang K., Peng Y., Renzetti M., Boyce R., Falcioni F., Garippa R., and Olivier A.R. Identification of a novel class of orally active pyrimido[5,4-3][1,2,4]triazine-5,7-diamine-based hypoglycemic agents with protein tyrosine phosphatase inhibitory activity. Bioorg. Med. Chem. Lett. 13 17 (2003) 2895-2898